Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Next Previous
Trial Profile

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Capecitabine; Cetuximab; Docetaxel; Fluorouracil; Methotrexate; Paclitaxel; Tegafur
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EAGLE
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 04 Jun 2024 Clinical data and imaging data of patient from this study were used to evaluate the impact of inter-lesion heterogeneity on patient's response, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 20 Feb 2023 Results of pooled analysis assessing the tumor mutational burden (TMB) and outcomes in the phase 2 HAWK/CONDOR (n=153) and phase 3 EAGLE (n=247) studies of durvalumab with or without tremelimumab in platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma, published in the Clinical Cancer Research.
  • 12 Dec 2020 This trial is completed in Belgium, Croatia, Czech Republic, Germany and Hungary (Global End Date: 13 Nov 2020), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top